QL2107
Sponsors
Qilu Pharmaceutical Co. Ltd., Qilu Pharmaceutical Co., Ltd.
Conditions
Advanced Solid TumorCarcinoma, Non-Small-Cell LungNSCLCNon-small cell lung cancerTumor
Phase 1
A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults
NCT06173011
Start: 2023-12-12End: 2024-07-31Target: 168Updated: 2024-01-23
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
RecruitingNCT06911827
Start: 2025-05-09End: 2028-12-01Target: 90Updated: 2026-02-25
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
RecruitingNCT07256782
Start: 2025-10-24End: 2028-05-31Target: 444Updated: 2025-12-01
Phase 3
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
RecruitingNCT06754644
Start: 2025-01-15End: 2026-12-31Target: 808Updated: 2025-06-10
A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison with Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects with Resected Non-Small Cell Lung Cancer.
RecruitingCTIS2024-519883-42-00
Start: 2025-10-08Target: 52Updated: 2025-12-15
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingNCT07162883
Start: 2025-09-01End: 2027-05-31Target: 122Updated: 2025-09-09